CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-05-18 | DORSA CAROLINE Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2017-05-18 | FORMELA JEAN FRANCOIS Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2017-05-18 | GORDON CARL L Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2017-05-18 | KARSEN PERRY A Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2017-03-10 | Atlas Venture Associates IX, L.P. 10% owner | Sale | −5,504 | $14.06 | $77K | 0 |
| 2017-03-10 | FORMELA JEAN FRANCOIS Director | Sale | −5,504 | $14.06 | $77K | 0 |
| 2017-03-09 | Atlas Venture Associates IX, L.P. 10% owner | Sale | −15,628 | $13.85 | $216K | 5,504 |
| 2017-03-09 | FORMELA JEAN FRANCOIS Director | Sale | −15,628 | $13.85 | $216K | 5,504 |
| 2017-03-03 | Novartis Institutes for BioMedical Research, Inc. 10% owner | Other acquisition | +79,245 | 5,652,903 | ||
| 2017-03-03 | Atlas Venture Fund IX, L.P. 10% owner | Other disposition | −700,000 | 3,729,788 | ||
| 2017-01-06 | Heifner Nicole SVP, Accounting | Grant or award · Stock Option (right to buy) | +28,500 | 28,500 | ||
| 2017-01-06 | Morrissey David V SVP, Platform & Delivery Tech | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2017-01-06 | Barnes Thomas M. SVP, R&D eXtellia | Grant or award · Stock Option (right to buy) | +50,500 | 50,500 | ||
| 2017-01-06 | LEONARD JOHN M. EVP, R&D | Grant or award · Stock Option (right to buy) | +95,000 | 95,000 | ||
| 2017-01-06 | Rivera Jose E EVP, General Counsel & Ops | Grant or award · Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2017-01-06 | Bermingham Nessan President & CEO | Grant or award · Stock Option (right to buy) | +270,000 | 270,000 | ||
| 2017-01-03 | Bell Graeme EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +210,000 | 210,000 | ||
| 2016-05-11 | ORBIMED ADVISORS LLC Director | Conversion | +1,847,400 | 1,847,400 | ||
| 2016-05-11 | ORBIMED ADVISORS LLC Director | Conversion | +564,780 | 2,412,180 | ||
| 2016-05-11 | ORBIMED ADVISORS LLC Director | Purchase | +191,466 | $18.00 | $3.4M | 2,603,646 |
Page 37 of 40 · 783 trades